{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:23:04Z","timestamp":1773220984091,"version":"3.50.1"},"reference-count":49,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["SAF-2017-88089-R"],"award-info":[{"award-number":["SAF-2017-88089-R"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>An effective vaccine against Human Immunodeficiency Virus (HIV) still remains the best solution to provide a sustainable control and\/or eradication of the virus. We have previously generated the HIV-1 vaccine modified vaccinia virus Ankara (MVA)-B, which exhibited good immunogenicity profile in phase I prophylactic and therapeutic clinical trials, but was unable to prevent viral rebound after antiretroviral (ART) removal. To potentiate the immunogenicity of MVA-B, here we described the design and immune responses elicited in mice by a new T cell multi-epitopic B (TMEP-B) immunogen, vectored by DNA, when administered in homologous or heterologous prime\/boost regimens in combination with MVA-B. The TMEP-B protein contained conserved regions from Gag, Pol, and Nef proteins including multiple CD4 and CD8 T cell epitopes functionally associated with HIV control. Heterologous DNA-TMEP\/MVA-B regimen induced higher HIV-1-specific CD8 T cell responses with broader epitope recognition and higher polyfunctional profile than the homologous DNA-TMEP\/DNA-TMEP or the heterologous DNA-GPN\/MVA-B combinations. Moreover, higher HIV-1-specific CD4 and Tfh immune responses were also detected using this regimen. After MVA-B boost, the magnitude of the anti-VACV CD8 T cell response was significantly compromised in DNA-TMEP-primed animals. Our results revealed the immunological potential of DNA-TMEP prime\/MVA-B boost regimen and supported the application of these combined vectors in HIV-1 prevention and\/or therapy.<\/jats:p>","DOI":"10.3390\/v10080424","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T11:27:13Z","timestamp":1534159633000},"page":"424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B"],"prefix":"10.3390","volume":"10","author":[{"given":"Beatriz","family":"Perdiguero","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh C.","family":"Raman","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"S\u00e1nchez-Corzo","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9473-283X","authenticated-orcid":false,"given":"Carlos Oscar","family":"S. Sorzano","sequence":"additional","affiliation":[{"name":"Biocomputing Unit, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-7114","authenticated-orcid":false,"given":"Jos\u00e9 Ram\u00f3n","family":"Valverde","sequence":"additional","affiliation":[{"name":"Scientific Computing Service, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Esteban","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-7935","authenticated-orcid":false,"given":"Carmen Elena","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1016\/j.vaccine.2011.08.098","article-title":"Safety and immunogenicity of a modified pox vector-based HIV\/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)","volume":"29","author":"Garcia","year":"2011","journal-title":"Vaccine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11468","DOI":"10.1128\/JVI.05165-11","article-title":"The HIV\/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens","volume":"85","author":"Gomez","year":"2011","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Guardo, A.C., Gomez, C.E., Diaz-Brito, V., Pich, J., Arnaiz, J.A., Perdiguero, B., Garcia-Arriaza, J., Gonzalez, N., Sorzano, C.O.S., and Jimenez, L. (2017). Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186602"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gomez, C.E., Perdiguero, B., Garcia-Arriaza, J., Cepeda, V., Sanchez-Sorzano, C.O., Mothe, B., Jimenez, J.L., Munoz-Fernandez, M.A., Gatell, J.M., and Lopez Bernaldo de Quiros, J.C. (2015). A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141456"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jac\/dkv046","article-title":"Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1","volume":"70","author":"Mothe","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00726-013-1526-9","article-title":"Peptides for immunological purposes: Design, strategies and applications","volume":"45","author":"Gori","year":"2013","journal-title":"Amino Acids"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.vaccine.2015.12.021","article-title":"Control of HIV-1 replication in vitro by vaccine-induced human CD8+ T cells through conserved subdominant pol epitopes","volume":"34","author":"Ahmed","year":"2016","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"Borthwick","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.4049\/jimmunol.1600697","article-title":"DNA prime-boost vaccine regimen to increase breadth, magnitude, and cytotoxicity of the cellular immune responses to subdominant Gag epitopes of simian immunodeficiency virus and HIV","volume":"197","author":"Hu","year":"2016","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Letourneau, S., Im, E.J., Mashishi, T., Brereton, C., Bridgeman, A., Yang, H., Dorrell, L., Dong, T., Korber, B., and McMichael, A.J. (2007). Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000984"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12967-015-0392-5","article-title":"A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques","volume":"13","author":"Mothe","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2016.3","article-title":"Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection","volume":"24","author":"Ondondo","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1128\/JVI.02370-14","article-title":"Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance","volume":"89","author":"Yang","year":"2015","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hayton, E.J., Rose, A., Ibrahimsa, U., Del Sorbo, M., Capone, S., Crook, A., Black, A.P., Dorrell, L., and Hanke, T. (2014). Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus Ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101591"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Moyo, N., Borthwick, N.J., Wee, E.G., Capucci, S., Crook, A., Dorrell, L., and Hanke, T. (2017). Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA\/simian adenovirus\/MVA vaccine regimens. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181382"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1128\/JVI.03246-12","article-title":"High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome","volume":"87","author":"Gomez","year":"2013","journal-title":"J. Virol."},{"key":"ref_17","first-page":"52","article-title":"HIV sequence databases","volume":"5","author":"Kuiken","year":"2003","journal-title":"AIDS Rev."},{"key":"ref_18","first-page":"656","article-title":"BLAT\u2014The BLAST-like alignment tool","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1073\/pnas.92.15.6773","article-title":"Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells","volume":"92","author":"Ward","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.vaccine.2006.09.090","article-title":"Head-to-head comparison on the immunogenicity of two HIV\/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B","volume":"25","author":"Gomez","year":"2007","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/JVI.00427-06","article-title":"Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB\/c mice","volume":"80","author":"Tscharke","year":"2006","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Najera, J.L., Gomez, C.E., Garcia-Arriaza, J., Sorzano, C.O., and Esteban, M. (2010). Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011406"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"Spice: Exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00253-011-3297-0","article-title":"Improved expression of secretory and trimeric proteins in mammalian cells via the introduction of a new trimer motif and a mutant of the tpa signal sequence","volume":"91","author":"Wang","year":"2011","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1479-5876-9-208","article-title":"Definition of the viral targets of protective HIV-1-specific T cell responses","volume":"9","author":"Mothe","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1128\/JVI.00020-15","article-title":"Clinical control of HIV-1 by cytotoxic t cells specific for multiple conserved epitopes","volume":"89","author":"Murakoshi","year":"2015","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1128\/JVI.03033-12","article-title":"HIV-1 conserved-element vaccines: Relationship between sequence conservation and replicative capacity","volume":"87","author":"Rolland","year":"2013","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mothe, B., Llano, A., Ibarrondo, J., Zamarreno, J., Schiaulini, M., Miranda, C., Ruiz-Riol, M., Berger, C.T., Herrero, M.J., and Palou, E. (2012). Ctl responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029717"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yusim, K., Korber, B.T., Brander, C., Barouch, D., de Boer, R., Haynes, B.F., Koup, R., Moore, J.P., Walker, B.D., and Watkins, D. (2016). HIV Molecular Immunology 2015.","DOI":"10.2172\/1248095"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1128\/JVI.78.9.4463-4477.2004","article-title":"Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides","volume":"78","author":"Kaufmann","year":"2004","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Laher, F., Ranasinghe, S., Porichis, F., Mewalal, N., Pretorius, K., Ismail, N., Buus, S., Stryhn, A., Carrington, M., and Walker, B.D. (2017). HIV controllers exhibit enhanced frequencies of major histocompatibility complex class II tetramer+ Gag-specific CD4+ T cells in chronic clade C HIV-1 infection. J. Virol., 91.","DOI":"10.1128\/JVI.02477-16"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1128\/JVI.00728-14","article-title":"Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control","volume":"88","author":"Schieffer","year":"2014","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"321974","DOI":"10.1155\/2014\/321974","article-title":"Characterization of the protective HIV-1 CTL epitopes and the corresponding HLA class I alleles: A step towards designing CTL based HIV-1 vaccine","volume":"2014","author":"Chakraborty","year":"2014","journal-title":"Adv. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","article-title":"Follicular helper T cells","volume":"34","author":"Vinuesa","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/imr.12512","article-title":"Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem","volume":"275","author":"Lee","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"298ra120","DOI":"10.1126\/scitranslmed.aab3964","article-title":"Quality and quantity of Tfh cells are critical for broad antibody development in shivad8 infection","volume":"7","author":"Yamamoto","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hancock, G., Yang, H., Yorke, E., Wainwright, E., Bourne, V., Frisbee, A., Payne, T.L., Berrong, M., Ferrari, G., and Chopera, D. (2015). Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004658"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kulkarni, V., Valentin, A., Rosati, M., Alicea, C., Singh, A.K., Jalah, R., Broderick, K.E., Sardesai, N.Y., Le Gall, S., and Mothe, B. (2014). Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086254"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1128\/CVI.00587-14","article-title":"Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB\/C mice","volume":"21","author":"Ondondo","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hu, X., Valentin, A., Cai, Y., Dayton, F., Rosati, M., Ramirez-Salazar, E.G., Kulkarni, V., Broderick, K.E., Sardesai, N.Y., and Wyatt, L.S. (2018). DNA-vaccine induced long-lasting cytotoxic T cells targeting conserved elements of HIV Gag are boosted upon DNA or rMVA vaccination. Hum. Gene Ther.","DOI":"10.1089\/hum.2018.065"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12793","DOI":"10.1128\/JVI.02016-14","article-title":"Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome","volume":"88","author":"Streeck","year":"2014","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.immuni.2015.12.011","article-title":"Circulating HIV-specific interleukin-21+ CD4+ T cells represent peripheral Tfh cells with antigen-dependent helper functions","volume":"44","author":"Schultz","year":"2016","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.immuni.2013.08.031","article-title":"Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses","volume":"39","author":"Locci","year":"2013","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Claireaux, M., Galperin, M., Benati, D., Nouel, A., Mukhopadhyay, M., Klingler, J., de Truchis, P., Zucman, D., Hendou, S., and Boufassa, F. (2018). A high frequency of HIV-specific circulating follicular helper t cells is associated with preserved memory B cell responses in HIV controllers. mBio, 9.","DOI":"10.1128\/mBio.00317-18"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fimmu.2013.00421","article-title":"CD4+ T cell priming as biomarker to study immune response to preventive vaccines","volume":"4","author":"Ciabattini","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Buchbinder, S.P., Grunenberg, N.A., Sanchez, B.J., Seaton, K.E., Ferrari, G., Moody, M.A., Frahm, N., Montefiori, D.C., Hay, C.M., and Goepfert, P.A. (2017). Immunogenicity of a novel clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179597"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/aid.2016.0251","article-title":"Three-year durability of immune responses induced by HIV-DNA and HIV-modified vaccinia virus Ankara and effect of a late HIV-modified vaccinia virus Ankara boost in tanzanian volunteers","volume":"33","author":"Joachim","year":"2017","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Thompson, M., Heath, S.L., Sweeton, B., Williams, K., Cunningham, P., Keele, B.F., Sen, S., Palmer, B.E., Chomont, N., and Xu, Y. (2016). DNA\/MVA vaccination of HIV-1 infected participants with viral suppression on antiretroviral therapy, followed by treatment interruption: Elicitation of immune responses without control of re-emergent virus. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163164"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3018(18)30039-0","article-title":"Barriers and strategies to achieve a cure for HIV","volume":"5","author":"Pitman","year":"2018","journal-title":"Lancet HIV"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/8\/424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:18:30Z","timestamp":1760195910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/8\/424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,13]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["v10080424"],"URL":"https:\/\/doi.org\/10.3390\/v10080424","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,13]]}}}